2.1
Regorafenib (Stivarga, Bayer) is indicated as 'monotherapy for the treatment of adult patients with hepatocellular carcinoma who have been previously treated with sorafenib'.
2 Information about regorafenib
Marketing authorisation indication
Dosage in the marketing authorisation
2.2
160 mg (4×40 mg tablets) orally once daily for 3 weeks followed by 1 week off therapy. A 4‑week period is considered a treatment cycle.
Price
2.3
The list price per treatment cycle for 160 mg of regorafenib is £3,744.00 (excluding VAT; BNF [accessed October 2018]). The company has a commercial arrangement. This makes regorafenib available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.